Sugi Predict

Sugi Predict / Compounds / SCHEMBL7082827

SCHEMBL7082827

SCHEMBL7082827

S=C(NCCc1ccccc1)Nc1cnccn1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.72
▸ RAB9A P51151 8/20 0.72
▸ ALOX12 P18054 2/20 0.72
▸ BCL6 P41182 1/20 0.65
▸ SMN1; SMN2 Q16637 8/20 0.62
▸ LMNA P02545 5/20 0.62
▸ KMT2A Q03164 5/20 0.62
▸ PKM P14618 2/20 0.62
▸ NPC1 O15118 4/20 0.57
▸ MAOA P21397 1/20 0.57
▸ MAOB P27338 1/20 0.57
▸ MAPT P10636 5/20 0.57
▸ KDM4E B2RXH2 4/20 0.57
▸ GALR3 O60755 1/20 0.57
▸ NR2F2 P24468 1/20 0.57
▸ HTT P42858 1/20 0.57
▸ MAPK1 P28482 3/20 0.55
▸ MEN1 O00255 4/20 0.53
▸ GAA P10253 2/20 0.52
▸ TAAR1 Q96RJ0 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29352156 0.84 ALDH1A1 (1.00) ALDH1A1RAB9AALOX12BCL6SMN1; SMN2
SCHEMBL6952754 0.84 ALDH1A1 (1.00) ALDH1A1RAB9AALOX12BCL6SMN1; SMN2
SCHEMBL6958381 0.80 ALDH1A1 (0.47) ALDH1A1RAB9AALOX12BCL6SMN1; SMN2
SCHEMBL6965322 0.78 ALDH1A1 (0.65) ALDH1A1RAB9AALOX12SMN1; SMN2LMNA
SCHEMBL6961902 0.78 RAB9A (0.73) ALDH1A1RAB9AALOX12BCL6SMN1; SMN2
SCHEMBL3956283 0.77 ALDH1A1 (0.70) ALDH1A1RAB9ASMN1; SMN2KMT2ANPC1
SCHEMBL7624466 0.77 ALDH1A1 (1.00) ALDH1A1RAB9AALOX12BCL6SMN1; SMN2
SCHEMBL29352042 0.77 ALDH1A1 (1.00) ALDH1A1RAB9AALOX12BCL6SMN1; SMN2
SCHEMBL29355043 0.77 ALDH1A1 (1.00) ALDH1A1RAB9AALOX12BCL6SMN1; SMN2
SCHEMBL6959672 0.77 RAB9A (0.79) ALDH1A1RAB9AALOX12BCL6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317787-A1 ORGANIC ELECTROLUMINESCENT DEVICE Beijing Summer Sprout Technology Co., Ltd. (CN) 2024-09-26 — — US claimed
US-20240298520-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-09-05 — — US claimed
US-20240251654-A1 ORGANIC ELECTROLUMINESCENT DEVICE Beijing Summer Sprout Technology Co., Ltd. (CN) 2024-07-25 — — US claimed
US-20230144846-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-05-11 — — US claimed
CN-115343667-A Mutual inductor intelligent test system 大连北方互感器集团有限公司 2022-11-15 — — CN claimed
WO-2026086378-A1 TETRADENTATE CYCLOMETALATED PLATINUM (II) COMPLEX GUEST PHOSPHORESCENT MATERIAL BASED ON 2,3',5'-SUBSTITUTED 1,1'-BIPHENYL STRUCTURE, AND USE THEREOF 浙江工业大学 2026-04-30 — — WO disclosed
US-20250329413-A1 GENE EXPRESSION SIGNATURE OF HYPERPROGRESSIVE DISEASE (HPD) IN PATIENTS AFTER ANTI-PD-1 IMMUNOTHERAPY MEDICAL COLLEGE WISCONSIN INC (US) 2025-10-23 — — US disclosed
US-20250295718-A1 CHIMERIC HSV EXPRESSING HIL21 TO BOOST ANTI-TUMOR IMMUNE ACTIVITY RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL 2025-09-25 — — US disclosed
US-12380963-B2 Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) 2025-08-05 — — US disclosed
EP-4430199-A2 CHIMERIC HSV EXPRESSING HIL21 TO BOOST ANTI-TUMOR IMMUNE ACTIVITY Research Institute at Nationwide Children's Hospital (US) 2024-09-18 — — EP disclosed
US-20240298520-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2024-09-05 — — US disclosed
CN-114414274-B Measurement and control system of closed refrigeration cycle test device 势加透博(重庆)科技有限公司 2024-07-19 — — CN disclosed
CN-115343667-A Mutual inductor intelligent test system 大连北方互感器集团有限公司 2022-11-15 — — CN disclosed
CN-114414274-A Measurement and control system of closed refrigeration cycle test device 势加透博(重庆)科技有限公司 2022-04-29 — — CN disclosed
CN-112349788-B Artificial heterogeneous synapse device with two-dimensional/zero-dimensional mixed structure and preparation method thereof 复旦大学 2022-02-08 — — CN disclosed
US-11230599-B2 Tumor mutational load MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2022-01-25 — — US disclosed
EP-0540143-B1 Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB (SE) 2003-02-05 — — EP disclosed
US-5714503-A Compounds and methods for inhibition of HIV and related viruses MEDIVIR AB (SE) 1998-02-03 — — US disclosed
US-5593993-A VIRICIDES FOR HTLV TREATMENT OF AIDS MEDIVIR AB (SE) 1997-01-14 — — US disclosed
EP-0540143-A2 Compounds and methods for inhibition of HIV and related viruses Medivir Aktiebolag (SE) 1993-05-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144846-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OXER1, OCIAD1, OCIAD2 ALDH1A1 501/4885RAB9A 819/4885ALOX12 680/4885
US-20240251654-A1 ORGANIC ELECTROLUMINESCENT DEVICE LEF1, EFNA1, EML4 ALDH1A1 131/4885RAB9A 2013/4885ALOX12 1207/4885
US-20240317787-A1 ORGANIC ELECTROLUMINESCENT DEVICE EPCAM, ORC3, OCIAD1 ALDH1A1 130/4885RAB9A 2646/4885ALOX12 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.